VCYT
Veracyte, Inc. · Healthcare · Medical - Diagnostics & Research
动量输入(同类管理人):
持有人广度 -6.2% ·
股份流向 -12.5% ·
净新建仓位 -6.7%
· 公式
广泛减持:持股数量下降,持有人数量减少
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q1 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 42.87K | $1.94M | n/a | n/a |
| Q2 2026 | 117 | +3 | 67.53M | $3.96B | +9 | −7 |
| Q1 2026 | 118 | +6 | 67.37M | $2.17B | +10 | −4 |
| Q4 2025 | 112 | 0 | 69.04M | $2.91B | +2 | −2 |
| Q3 2025 | 18 | -2 | 46.98M | $1.61B | n/a | −3 |
| Q2 2025 | 18 | 0 | 39.06M | $1.06B | +1 | −1 |
| Q1 2025 | 15 | -1 | 15.53M | $460.45M | n/a | −1 |
| Q4 2024 | 16 | +1 | 17.75M | $702.81M | +1 | n/a |
| Q3 2024 | 14 | +1 | 14.22M | $484.20M | +3 | −2 |
| Q2 2024 | 13 | n/a | 18.04M | $390.85M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 3.94M | -6.3% | $116.80M | 1.2% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.85M | -5.7% | $114.25M | 0.0% | ▼ Trim | 4 | SEC ↗ ×6 |
| 3 | State Street Global Advisors ✦ (被动) | 3.16M | +8.5% | $93.64M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 1.93M | +5.2% | $57.38M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Fisher Asset Management ✦ | 848.61K | +0.3% | $25.16M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 832.00K | +38.5% | $24.67M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 490.85K | -22.7% | $14.55M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 195.89K | -14.9% | $5.81M | 0.0% | ▼ Trim | 4 | SEC ↗ ×5 |
| 9 | Norges Bank ✦ (被动) | 100.50K | -55.5% | $2.98M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 57.80K | +19.4% | $1.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 56.77K | -80.8% | $1.68M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Point72 Asset Management ✦ | 25.16K | -95.2% | $745,964 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 18.88K | -5.9% | $559,822 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Millennium Management ✦ | 8.87K | -96.3% | $262,966 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Marshall Wace ✦ | 8.33K | -99.1% | $247,014 | 0.0% | ▼ Trim | 3 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| D. E. Shaw & Co. | $3.41M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 333 持有人, 87.61M 股份, $2.75B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 4.01K 股 · $160,600
Director · 5.00K 股 · $204,747
Officer · 1.10K 股 · $48,039
Officer · 2.48K 股 · $106,030
Officer · 1.18K 股 · $51,364
Officer · 2.71K 股 · $118,105
Officer · 10.40K 股 · $446,305
Officer · 2.15K 股 · $92,173
Director · 1.86K 股 · $80,096
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论